Clinical Trial Update: Safety Study of MT-4666 in Subjects With Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 safety study of MT-4666 in Alzheimer's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• MT-4666

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED